Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

RSS icon
Thumbnail

Walmart acquires health management app CareZone

Walmart has expanded its digital health services by acquiring CareZone, a technology platform and mobile app that allows individuals and families to manage medicine and chronic disease.

Thumbnail

Physicians estimate return to normal in August 2021

It will be more than a year for the U.S. healthcare industry to return to normal, with physicians expecting the new normal to be sometime around August 2021—once a vaccine for COVID-19 has been distributed.

Thumbnail

HHS finalizes rule repealing Obama-era protections for trans patients

The rule eliminates provisions of a 2016 rule from the Obama administration that attempted to protect trans patients from discrimination.

Thumbnail

Kaiser Permanente to return $500M in coronavirus aid

Kaiser Permanente is among a handful of major healthcare organizations that have promised to refund the government millions in aid meant to help health systems and hospitals deal with the COVID-19 pandemic.

Cost of coronavirus tests varies, but high costs are exceptions

Reports of sky-high costs for coronavirus testing may be the exception, with the majority of testing being “relatively tame” in cost, according to an analysis by Axios.

Thumbnail

Trump promises to break US away from WHO

President Trump has stated he wants to terminate the United States’ relationship with the World Health Organization.

Thumbnail

CVS facing lawsuit from six Blue Cross insurers

CVS Health has been accused of overcharging for generic medications in a new lawsuit brought forth by six Blue Cross Blue Shield plans.

Thumbnail

More Part D plans will likely offer $35 monthly co-pays for insulin in 2021

More than 1,750 standalone Medicare Part D prescription drug plans and MA plans have applied to offer insulin at a maximum $35 copay for a month’s supply of the drug for the 2021 plan year, CMS announced.

Displaying 753 - 760 of 2773

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup